Benjamin F. Edwards & Company Inc. Has $1.27 Million Stock Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Benjamin F. Edwards & Company Inc. lifted its holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 6,439.6% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 169,900 shares of the company’s stock after purchasing an additional 167,302 shares during the quarter. Benjamin F. Edwards & Company Inc. owned about 0.07% of Recursion Pharmaceuticals worth $1,274,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of RXRX. Wedmont Private Capital lifted its holdings in shares of Recursion Pharmaceuticals by 11.8% in the first quarter. Wedmont Private Capital now owns 18,943 shares of the company’s stock valued at $172,000 after purchasing an additional 2,000 shares in the last quarter. Interchange Capital Partners LLC lifted its stake in Recursion Pharmaceuticals by 7.3% in the 2nd quarter. Interchange Capital Partners LLC now owns 34,580 shares of the company’s stock valued at $268,000 after acquiring an additional 2,349 shares in the last quarter. Amalgamated Bank boosted its position in Recursion Pharmaceuticals by 52.4% during the 2nd quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock worth $54,000 after acquiring an additional 2,459 shares during the last quarter. Victory Capital Management Inc. grew its stake in shares of Recursion Pharmaceuticals by 13.5% during the 2nd quarter. Victory Capital Management Inc. now owns 21,891 shares of the company’s stock worth $164,000 after acquiring an additional 2,598 shares in the last quarter. Finally, Green Alpha Advisors LLC raised its holdings in shares of Recursion Pharmaceuticals by 6.7% in the first quarter. Green Alpha Advisors LLC now owns 72,434 shares of the company’s stock valued at $722,000 after purchasing an additional 4,563 shares during the last quarter. 89.06% of the stock is owned by institutional investors.

Recursion Pharmaceuticals Stock Down 1.9 %

Shares of RXRX stock opened at $6.67 on Tuesday. Recursion Pharmaceuticals, Inc. has a 52-week low of $4.97 and a 52-week high of $15.74. The stock has a market cap of $1.59 billion, a price-to-earnings ratio of -4.17 and a beta of 0.82. The firm’s 50-day moving average is $7.12 and its 200-day moving average is $8.29. The company has a debt-to-equity ratio of 0.04, a quick ratio of 6.07 and a current ratio of 6.07.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.05). The business had revenue of $14.42 million during the quarter, compared to analyst estimates of $11.96 million. Recursion Pharmaceuticals had a negative net margin of 755.37% and a negative return on equity of 79.47%. The business’s quarterly revenue was up 30.9% on a year-over-year basis. During the same period in the previous year, the business earned ($0.38) earnings per share. Sell-side analysts predict that Recursion Pharmaceuticals, Inc. will post -1.58 EPS for the current year.

Insiders Place Their Bets

In other news, Director Blake Borgeson sold 11,447 shares of the firm’s stock in a transaction dated Tuesday, July 9th. The shares were sold at an average price of $7.32, for a total transaction of $83,792.04. Following the completion of the sale, the director now owns 7,167,110 shares in the company, valued at approximately $52,463,245.20. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other news, COO Tina Marriott sold 6,000 shares of the firm’s stock in a transaction that occurred on Thursday, July 25th. The shares were sold at an average price of $8.13, for a total transaction of $48,780.00. Following the transaction, the chief operating officer now directly owns 535,457 shares of the company’s stock, valued at $4,353,265.41. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock in a transaction on Tuesday, July 9th. The shares were sold at an average price of $7.32, for a total value of $83,792.04. Following the completion of the transaction, the director now directly owns 7,167,110 shares of the company’s stock, valued at $52,463,245.20. The disclosure for this sale can be found here. Insiders sold a total of 231,682 shares of company stock valued at $1,633,304 over the last ninety days. 15.75% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on RXRX. Leerink Partners decreased their target price on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating for the company in a research report on Tuesday, September 3rd. Jefferies Financial Group decreased their price objective on Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating for the company in a report on Tuesday, September 3rd. Needham & Company LLC dropped their target price on Recursion Pharmaceuticals from $16.00 to $11.00 and set a “buy” rating on the stock in a report on Wednesday, September 4th. Finally, KeyCorp decreased their price target on Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating for the company in a research note on Thursday, July 11th. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $9.40.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.